A 28-day study of gal-101 for mild to moderate Alzheimer's
Part of Brain & nervous system clinical trials.
This study tests an experimental medication called GAL-101, which may help slow down or reduce the effects of Alzheimer's disease. It is a 28-day trial for people with mild to moderate symptoms, and the goal is to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 50 and 85 years old.
- You should have a diagnosis of mild or moderate Alzheimer's disease.
- You need to have evidence of amyloid protein buildup in the brain (confirmed by a PET scan, spinal fluid test, or blood test).
- You must have a caregiver or family member who can help you for at least 10 hours each week.
- You should have had some memory decline over the past year.
- You cannot have ever been treated with an anti-amyloid antibody therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
This trial tests whether a supplement called Neuroaid II can help people with mild to moderate Alzheimer's disease. It is a pill taken alongside your usual Alzheimer's treatments, and the study aims to see if it can slow down memory decline.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
Hear when a new Mild to Moderate Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.